Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 22 July 2019 – On 7 May 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.
Under the programme initiated 7 May 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.7 billion in the period from 8 May 2019 to 7 August 2019.
Since the announcement as of 15 July 2019, the following transactions have been made under the programme:
|Accumulated, last announcement||5,788,400||1,909,190,965|
|15 July 2019||135,000||317.33||42,839,778|
|16 July 2019||135,000||318.80||43,038,633|
|17 July 2019||135,000||321.53||43,407,138|
|18 July 2019||135,000||321.93||43,460,372|
|19 July 2019||135,000||318.54||43,002,719|
|Accumulated under the programme||6,463,400||2,124,939,605|
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 28,806,543 B shares of DKK 0.20, corresponding to 1.2% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 19 July 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 21,639,904 B shares at an average share price of DKK 326.24 per B share equal to a transaction value of DKK 7,059,893,206.
|Anne Margrethe Hauge||+45 4442 firstname.lastname@example.org|
|Ken Inchausti (US)||+1 609 240 email@example.com|
|Peter Hugreffe Ankersen||+45 3075 firstname.lastname@example.org|
|Valdemar Borum Svarrer||+45 3079 email@example.com|
|Ann Søndermølle Rendbæk||+45 3075 firstname.lastname@example.org|
|Kristoffer Due Berg (US)||+1 609 235 email@example.com|
Company announcement No 42 / 2019
Upcoming Life Sciences Events
- December 2019
- Marseille: BioFIT
- London: Genesis 2019
- London: The Pharma Business Development Course